Published in Nat Rev Nephrol on February 01, 2011
Treatment of HCV patients before and after renal transplantation. Hepat Mon (2011) 0.80
The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virus. PLoS One (2011) 0.80
Virus-drug interactions--molecular insight into immunosuppression and HCV. Nat Rev Gastroenterol Hepatol (2012) 0.77
Increased risk of hepatic complications in kidney transplantation with chronic virus hepatitis infection: A nationwide population-based cohort study. Sci Rep (2016) 0.75
Pretransplant Hepatitis B Viral Infection Increases Risk of Death After Kidney Transplantation: A Multicenter Cohort Study in Korea. Medicine (Baltimore) (2016) 0.75
A study on the biochemical and the morphological changes in the liver in renal transplant recipients with an evidence of the HBV and the HCV infections. J Clin Diagn Res (2013) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology (2003) 10.11
Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med (2007) 9.44
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med (1998) 9.03
Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med (2003) 8.47
KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant (2009) 6.43
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Viral hepatitis C. Lancet (2003) 5.81
Diabetes mellitus after kidney transplantation in the United States. Am J Transplant (2003) 4.39
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology (2009) 4.00
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant (2007) 3.26
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl (2008) 3.00
Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology (2003) 2.76
KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int (2009) 2.72
Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology (1998) 2.67
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology (2004) 2.44
Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology (2002) 2.25
Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int (1998) 2.14
Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology (1999) 2.11
Antiviral drug-induced nephrotoxicity. Am J Kidney Dis (2005) 1.87
Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology (2002) 1.84
Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transplant (2008) 1.81
Antiviral resistance and hepatitis B therapy. Hepatology (2009) 1.67
Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant (2002) 1.60
Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant (2008) 1.55
A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet (1995) 1.54
Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation (2004) 1.45
Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int (2004) 1.43
The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation (1995) 1.43
Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant (2007) 1.40
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant (2005) 1.28
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol (2010) 1.27
Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis (2008) 1.17
HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant (2005) 1.15
Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int (2003) 1.14
Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation (2008) 1.13
Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol (1999) 1.12
Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology (2006) 1.10
Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant (2001) 1.10
Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant (2005) 1.08
The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant (2004) 1.07
Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant (2010) 1.06
Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation (2007) 1.06
Transplantation in the patient with hepatitis C. Transpl Int (2009) 1.06
Natural history of hepatitis B and C in renal allograft recipients. Transplantation (2005) 1.05
The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol (2007) 1.05
Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl (2002) 1.03
Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant (2003) 1.03
Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation (2004) 1.02
Long-term effect of hbs antigenemia on patient survival after renal transplantation. N Engl J Med (1977) 1.01
Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis (2001) 1.01
Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant (2005) 1.01
Hepatic disorders in chronic kidney disease. Nat Rev Nephrol (2010) 1.01
The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation (1985) 1.00
Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation (1998) 0.99
The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis (1997) 0.99
Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol (2003) 0.99
Hepatitis B virus infection and the dialysis patient. Semin Dial (2008) 0.97
Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation (2007) 0.97
Interferon-alpha-induced acute renal allograft rejection. Transplantation (1995) 0.95
Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol (2001) 0.94
Transplantation in the patient with hepatitis C. J Am Soc Nephrol (2000) 0.93
The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation (1996) 0.93
The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant (2004) 0.92
Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation (2008) 0.92
The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am J Kidney Dis (2004) 0.91
Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation (2004) 0.91
Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. Clin Nephrol (2009) 0.90
Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant (2001) 0.90
Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant (2006) 0.90
Hepatitis C virus infection and renal transplantation. Am J Kidney Dis (2001) 0.90
Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation (2010) 0.89
Pretransplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation. Transplantation (1998) 0.89
Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron (1996) 0.89
Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis (2000) 0.88
Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis (2003) 0.88
Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract (2005) 0.88
Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation (2005) 0.87
Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation (2008) 0.87
Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation (1987) 0.86
The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive. Transplantation (1991) 0.86
Kidney transplantation from anti-HBc+ donors: results from a retrospective Italian study. Transplantation (2006) 0.86
Hepatitis C, acute humoral rejection, and renal allograft survival. J Am Soc Nephrol (2004) 0.86
Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis (1999) 0.86
Interferon for hepatitis C virus in hemodialysis--an individual patient meta-analysis of factors associated with sustained virological response. Clin J Am Soc Nephrol (2009) 0.85
Immunosuppression induced by hepatitis C virus infection reduces acute renal-transplant rejection. Lancet (1995) 0.85
Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation (1997) 0.85
Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int (1998) 0.84
Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol (2002) 0.84
Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation (2001) 0.84
Review article: hepatitis C virus and calcineurin inhibition after renal transplantation. Aliment Pharmacol Ther (2005) 0.84
Hepatitis B surface antigenemia in renal transplant recipients. Increased mortality risk. JAMA (1979) 0.84
Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation (2006) 0.83
Prospective study on lamivudine-resistant hepatitis B in renal allograft recipients. Am J Transplant (2004) 0.82
Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation (2000) 0.82
Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant (2006) 1.09
Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation (2011) 1.02
Twelve-month pancreas graft function significantly influences survival following simultaneous pancreas-kidney transplantation. Clin J Am Soc Nephrol (2009) 0.99
The impact of human leukocyte antigen mismatching on sensitization rates and subsequent retransplantation after first graft failure in pediatric renal transplant recipients. Transplantation (2013) 0.98
Trends in immune function assay (ImmuKnow; Cylex™) results in the first year post-transplant and relationship to BK virus infection. Nephrol Dial Transplant (2011) 0.94
Acute kidney injury in kidney transplantation. Curr Opin Nephrol Hypertens (2013) 0.94
Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virus-associated nephropathy: a comparison of two reduction strategies. Clin J Am Soc Nephrol (2008) 0.93
The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression. Transplantation (2010) 0.93
Simultaneous pancreas-kidney versus deceased donor kidney transplant: can a fair comparison be made? Transplantation (2009) 0.92
An analysis of the lack of donor pancreas utilization from younger adult organ donors. Transplantation (2010) 0.92
The risk of acute rejection and the influence of induction agents in lower-risk African American kidney transplant recipients receiving modern immunosuppression. Clin Transplant (2014) 0.86
Single time point immune function assay (ImmuKnow) testing does not aid in the prediction of future opportunistic infections or acute rejection. Clin J Am Soc Nephrol (2010) 0.85
Long-term impact of donor-recipient size mismatching in deceased donor kidney transplantation and in expanded criteria donor recipients. Transplantation (2010) 0.83
Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Clin Transpl (2011) 0.83
Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity. Am J Transplant (2004) 0.83
Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. Transplantation (2009) 0.82
Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients. Transplantation (2009) 0.80
Removing financial disincentives to organ donation: an acceptable next step? Clin J Am Soc Nephrol (2012) 0.79
High dose intravenous immunoglobulin therapy for donor-specific antibodies in kidney transplant recipients with acute and chronic graft dysfunction. Transplantation (2014) 0.77
Standard criteria donor pancreas donation status is associated with improved kidney transplant outcomes. Clin Transplant (2009) 0.77
Preemptive retransplant for BK virus nephropathy without concurrent transplant nephrectomy. Transplantation (2010) 0.77
Page kidney causing reversible acute renal failure: an unusual complication of transplant biopsy. Transplantation (2005) 0.76
The pharmacokinetics and pharmacodynamics of TOL101, a murine IgM anti-human αβ T cell receptor antibody, in renal transplant patients. Clin Pharmacokinet (2014) 0.75
Current status of pancreas transplantation. Curr Opin Nephrol Hypertens (2016) 0.75
Live donor kidney - PAK versus SPK: how to decide? Curr Opin Organ Transplant (2017) 0.75
Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases. Clin Transpl (2010) 0.75
Donor specific antibodies before and after kidney transplant: the University of Colorado Experience. Clin Transpl (2013) 0.75
Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases. Clin Transpl (2009) 0.75
De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens. Exp Clin Transplant (2017) 0.75
High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts. Clin Transpl (2014) 0.75
Corticosteroid elimination in simultaneous liver-kidney transplantation recipients. Clin Transplant (2009) 0.75